

TCS/PR/SE-104/2022-23

October 25, 2022

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai - 400051 Symbol - TCS BSE Limited P. J. Towers, Dalal Street, Mumbai - 400001 Scrip Code No. 532540

Dear Sirs,

We are sending herewith copy of the Press Release titled "TCS Recognized as a Leader in IDC MarketScape for Life Science R&D Decentralized Clinical Trials Technology Solutions" which will be disseminated shortly.

The Press release is self-explanatory.

Thanking you,

Yours faithfully, For **Tata Consultancy Services Limited**

Pradeep Manohar Gaitonde Company Secretary

TATA CONSULTANCY SERVICES

TATA Consultancy Services Limited



For immediate use Press Release

TCS Recognized as a Leader in IDC MarketScape for Life Science R&D Decentralized Clinical Trials Technology Solutions

Tata Consultancy Services' End-To-End Offering for Decentralized Trials, TCS ADD™ Connected Clinical Trials

Cited as a Key Strength

NEW YORK | MUMBAI, October 25, 2022: Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS) has been named a Leader in the IDC MarketScape for Worldwide Life Science R&D Decentralized Clinical Trial (DCT) Technology Solutions¹.

According to the report, "TCS' differentiators include the breadth of DCT capabilities that it offers, the ease of implementation of its solutions, and its competitive pricing. Its value proposition for DCTs is its end-to-end integrated platform and its ecosystem play."

"The momentum towards adoption of digitalization of clinical trials has really accelerated in the past few years. We had however envisioned the shift towards decentralization in the clinical trials space early on and architected our solution accordingly. Consequently, when the pandemic hit, our customers were equipped to run studies leveraging our ready-to-use offerings such as eConsenting, Supply Management, smart medication management, BYOD configured patient and site app," said Rachna Malik, Global Head, TCS ADD™ platforms. "We believe our position as a Leader in the evaluation of DCT providers validates the rectitude in our vision, investment in intellectual property and resulting market success."

TCS ADD Connected Clinical Trials is a comprehensive suite of AI/ML-based platforms for decentralized trials. It provides a unified interface for patients and sites, facilitates collaboration with stakeholders such as regulators, sites, and health authorities, and enables patient-centric trials. The platform connects patients, sites, and sponsors through a variety of innovative sensors, smart medication packages, and mobile devices, to enhance trial outcomes. It caters to operations across the clinical studies lifecycle including e-consent, smart questionnaire (eCOA, diaries and surveys), an industry first supply management platform that brings together kit tracking, digital labels, and unit/dose tracking (medication adherence), and telemedicine.

The platform is comprehensive, interoperable and supports eco-system interplay, has multilingual capabilities, as well as the ability to be hosted on multi-cloud and multi-region. In addition, TCS ADD Connected Clinical Trials supports automated data collection, enables remote monitoring and oversight suitable for high frequency and a high volume of data.

"The DCT landscape is an ever-evolving ecosystem play, including a multitude of players bringing together a wide spectrum of innovative technologies. The secret sauce for scaling success will lie in integrating the right mix of partners and technologies, harmonizing workflows and dataflows, and building 'digital-first' strategies to provide patients and sites with an enriched, frictionless experience, while ensuring compliance at all costs," said **Dr Nimita Limaye, Research VP, Life Sciences R&D Strategy & Technology, IDC**. "The TCS ADD suite of modern and open platforms, and TCS' ability to drive cross-industry collaborations and expertise in technology implementation have made it a Leader in this report."

About TCS ADD™ platforms

TCS ADD™ is a suite of modern and open drug development platform for life sciences that enables digital ecosystems, simplifies data complexity and provides faster access to new and effective drugs for patients in

¹ IDC MarketScape: Worldwide Life Science R&D DCT Technology Solutions 2022 Vendor Assessment (doc #US49649022, September 2022)



For immediate use Press Release

need. The platform is powered by our proprietary cognitive artificial intelligence engine, data driven smart analytics and Internet of Things (IoT) that makes clinical trials more agile and safe. TCS ADD leverages the best of cloud architecture and personalized user experience design in compliance with quality guidelines and privacy regulations.

To know more visit <u>www.tcs.com/tcs-add</u> or email: <u>add.platform@tcs.com</u>

About IDC MarketScape:

IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of ICT (information and communications technology) suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor's position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.

About Tata Consultancy Services (TCS)

Tata Consultancy Services is an IT services, consulting and business solutions organization that has been partnering with many of the world's largest businesses in their transformation journeys for over 50 years. TCS offers a consulting-led, cognitive powered, integrated portfolio of business, technology and engineering services and solutions. This is delivered through its unique Location Independent Agile™ delivery model, recognized as a benchmark of excellence in software development.

A part of the Tata group, India's largest multinational business group, TCS has over 616,000 of the world's best-trained consultants in 55 countries. The company generated consolidated revenues of US \$25.7 billion in the fiscal year ended March 31, 2022, and is listed on the BSE (formerly Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. TCS' proactive stance on climate change and award-winning work with communities across the world have earned it a place in leading sustainability indices such as the MSCI Global Sustainability Index and the FTSE4Good Emerging Index. For more information, visit www.tcs.com

TCS media contacts:

Asia Pacific	Email: wenjian.lin@tcs.com Phone: +65 9695 9948
Australia and New Zealand	Email: kelly.ryan@tcs.com Phone: +61 422 989 682
Canada	Email: tiffany.fisher@tcs.com Phone: +1 416 999 2140
Europe	Email: joost.galema@tcs.com Phone: +31 615 903387
India	Email: saxena.kritika@tcs.com Phone: +91 22 6778 9999 Email: vanshika.sood@tcs.com Phone: +91 22 67789098
Middle East & Africa	Email: pragya.priyadarshini@tcs.com Phone: +971 528656700
Japan	Email: douglas.foote@tcs.com Phone: +81 80-2115-0989
Latin America	Email: alma.leal@tcs.com Phone: +521 55 2095 6098
UK	Email: peter.devery@tcs.com Phone: +44 20 3155 2421
USA	Email: james.sciales@tcs.com Phone: +1 917 981 7651